Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto
- Conditions
- ThalassemiaFertilityPregnancy
- Registration Number
- NCT00327639
- Lead Sponsor
- University Health Network, Toronto
- Brief Summary
Treatment of patients with beta thalassemia in North America has altered dramatically during the past 40 years, with improvements in transfusion therapy and introduction of iron chelation therapy. Thalassemia patients now enjoy an increased life expectancy to the fifth and sixth decades of life, with fertility and childbearing becoming important issues. Data regarding this important topic remain limited, without clear data regarding iron control including serial assessment of hepatic iron concentration, the need for assistance in becoming pregnant, and use of iron chelating agents during pregnancy. As the life expectancy increases and overall health improves in thalassemia, clear data on fertility, pregnancy complications, and the effect of pregnancy on maternal health in thalassemia patients are necessary since these will have a direct impact on patient care, quality of life, and patient expectations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
- Thalassemia, thalassemia intermedia or E-thalassemia patients in Toronto
- Subject has attempted conception
- Subject has any other form of blood disease
- Subject has not attempted conception
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Health Network, Toronto General Hospital
🇨🇦Toronto, Ontario, Canada